Determination of the cost-effective advantages of regimens of diabetes mellitus type 2 with modern DPP-4 inhibitors

  • T. I. Ivko Vinnitsa National Medical University Pirogov
  • T. A. Germanyuk Vinnitsa National Medical University Pirogov
Keywords: diabetes mellitus type 2, oral hypoglycemic drugs, dipeptidylpeptidase-4 inhibitors, ATC/DDD-analysis, cost-effectiveness analysis, sensitivity analysis

Abstract

Diabetes mellitus is a medical and social problem. The results of the pharmacoeconomical researches should be considered when choosing a rational pharmacotherapy.

The purpose of this research of treatment regimens of diabetes mellitus type 2 was a definition of the pharmacoeconomically justified schemes of therapy that include the modern dipeptidylpeptidase-4 inhibitors.

The research was based on the retrospective analysis of 747 medical histories of patients with type 2 diabetes mellitus. These patients were treated at the Vinnytsia Regional Endocrinology Clinic in 2011–2013. The following methods were used in the research: retrospective analysis, frequency analysis, analysis of individual parameters of the patients, ATC/DDD-analysis, cost–effectiveness analysis, and sensitivity analysis.

It has been found that the scheme of pharmacotherapy with metformin+saxagliptin was more expensive than another scheme of pharmacotherapy with metformin + sitagliptin, but effectiveness of these schemes did not differ significantly. Obtained results indicate the cost–effective advantages of the scheme of pharmacotherapy with metformin + sitagliptin. However, the sensitivity analysis showed the instability of the results of the pharmacoeconomic studies.

References

1. Sonsensus statement. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy // Diabetes Care. – 2009. – V. 32, N 1. – R. 193–203.
2. Nakaz vid 21. 12. 2012 r. № 1118 «Unifikovanij klinichnij protokol pervinnoyi ta vtorinnoyi (specializovanoyi) medichnoyi dopomogi».
3. Dedov I. I., Shestakova M. V., Ametov A. S. i dr. Konsensus soveta ekspertov Rossijskoj associacii endokrinologov po iniciacii i intensifikacii saharosnizhayushej terapii u bolnyh saharnym diabetom 2 tipa / Normativnye dokumenty. Saharnyj diabet. – 2011. – № 4. – S. 6–17.
4. Chan J. C., Scott R., Arjona Ferreira J. C. et al. Safety and efficasy of sitagliptin in patients with type 2 diabetes and chronic renal in sufficiency // Diabetes Obes. Metab. – 2008. – N 10 (7). – R. 545–555. Epub. 2008 Jun. 1.
5. A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus // J. Pharmacol. Pharmacother. Saxagliptin. – 2011. – V. 2, N 4. – P. 230–235.
6. Label and approval history of KOMBIGLYZE XR (Combination of saxagliptin and metformin hydrochloride extended release tablets) [Last accessed on 2011 Jan 31]. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory
7. Guidelines for ATC classification and DDD assignment. – 2013 – P. 15. Available at: www.whocc.no/atc_ddd_index/ www.moz.gov.ua/ua/register_prices_drugs
8. Postanova KM Ukrayini vid 5 veresnya 1996 r. № 1071 «Pro poryadok zakupivli likarskih zasobiv zakladami ta ustanovami ohoroni zdorov’ya, sho finansuyutsya z byudzhetu».
9. Postanova KM Ukrayini vid 17 zhovtnya 2008 r. № 955 «Pro zahodi shodo stabilizaciyi cin na likarski zasobi i virobi medichnogo priznachennya».
10. Postanova KM Ukrayini vid 25 bereznya 2009 r. № 333 «Deyaki pitannya derzhavnogo regulyuvannya cin na likarski zasobi i virobi medichnogo priznachennya».
11. Podatkovij kodeks Ukrayini (pidpunkt 197.1.27 punktu 197.1 statti 197 viklyucheno na pidstavi Zakonu № 1166-VII vid 27. 03. 2014, pidpunkt 193.1 v punktu 193.1 statti 193 dodano).
12. Linda D. Dresser, Michael S. Niederman, Joseph A. Paladino. Cost-effectiveness of Gatifloxacin vs Ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. Available at: www.publications.chestnet.org/pdfAccess.ashx?url
13. Yagudina R. I., Kulikov A. Yu., Arinina E. E. Farmakoekonomika saharnogo diabeta vtorogo tipa. – M.: OOO «Medicinskoe informacionnoe agentstvo», 2011. – S. 60–100.
Published
2019-02-12
How to Cite
Ivko, T. I., & Germanyuk, T. A. (2019). Determination of the cost-effective advantages of regimens of diabetes mellitus type 2 with modern DPP-4 inhibitors. Farmatsevtychnyi Zhurnal, (6), 29-34. Retrieved from https://pharmj.org.ua/index.php/journal/article/view/270
Section
Management of pharmacy